Differential expression of the hepatic transcript of ?-galactoside ?2,6-sialyltransferase in human colon cancer cell lines
Open Access
- 12 April 1999
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 81 (2) , 243-247
- https://doi.org/10.1002/(sici)1097-0215(19990412)81:2<243::aid-ijc13>3.0.co;2-o
Abstract
The activity of β‐galactoside α2,6‐sialyltransferase (ST6Gal.1), the enzyme responsible for the addition of sialic acid in α2,6‐linkage to N‐acetyllactosaminic (Galβ1,4GlcNAc) units of glycoconjugates, is increased in the vast majority of colon cancer specimens, and a positive correlation with an invasive phenotype has been suggested by several studies. In many tissues, ST6Gal.1 is regulated mainly at the transcriptional level through the use of different cell‐specific promoters which generate transcripts differing in their 5'‐untranslated regions. With the aim of understanding the molecular bases of the increased ST6Gal.1 expression in colon cancer, we investigated the expression of mRNA species in colon cancer cell lines and the relationship with enzyme activity and extent of α2,6‐sialylation of cell glycoproteins. All cell lines examined express the form containing the 5'‐untranslated exons Y and Z, typical of the “basal” expression of the gene, while others express also the liver transcript. This indicates that colon cancer cell lines can be grouped according to expression of the liver transcript of ST6Gal.1. The cell lines expressing only the Y+Z form display, in general, a lower activity:mRNA ratio, which might indicate reduced translational efficiency. The level of α2,6‐sialylation of cell glycoproteins, as determined by reactivity with the Sambucus nigra lectin, is closely associated with the level of enzyme activity. Int. J. Cancer 81:243–247, 1999.Keywords
This publication has 21 references indexed in Scilit:
- Differentiation-dependent expression of human?-galactoside?2,6-sialyltransferase mRNA in colon carcinoma CaCo-2 cellsGlycoconjugate Journal, 1996
- Characterization of a promoter region supporting transcription of a novel human β-galactoside α-2,6-sialyltransferase transcript in HepG2 cellsBiochimica et Biophysica Acta (BBA) - Gene Structure and Expression, 1995
- Enhanced activity of CMP-NeuAc:Galβ1-4GlcNAc:α2,6-sialyltransferase in metastasizing human colorectal tumor tissue and serum of tumor patientsCancer Letters, 1993
- Cell‐specific expression of human β‐galactoside α2,6‐sialyltransferase transcripts differing in the 5′ untranslated regionEuropean Journal of Biochemistry, 1993
- Human Golgi β‐galactoside α‐2,6‐sialyltransferase generates a group of sialylated B lymphocyte differentiation antigensEuropean Journal of Immunology, 1992
- Enhanced CMP‐NeuAc:Galβ1, 4GlcNAc‐R α2, 6 sialyltransferase activity of human colon cancer xenografts in athymic nude mice and of xenograft‐derived cell linesInternational Journal of Cancer, 1992
- α2, 6 sialylation ofN-acetyllactosaminic sequences in human colorectal cancer cell lines. Relationship with non-adherent growthInternational Journal of Cancer, 1991
- Postnatal development of rat colon epithelial cells is associated with changes in the expression of the β1,4-N-acetylgalactosaminyltransferase involved in the synthesis of Sda antigen of α2,6-sialyltransferase activity towards N-acetyl-lactosamineBiochemical Journal, 1990
- Complete cDNA sequence encoding human β-galactoside α-2, 6-sialyltransferaseNucleic Acids Research, 1990
- Increased CMP‐NeuAc:Galβ1,4GlcNAc‐R α2,6 sialyltransferase activity in human colorectal cancer tissuesInternational Journal of Cancer, 1989